lung cancer
Conditions
Interventions
None listed
Sponsors
Niigata university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cases meeting all of the following criteria will be considered eligible . (1) Patients with pathologically or clinically diagnosed stage III or IV primary lung cancer. (2) Patients receiving chemotherapy, molecular targeted therapy, immunotherapy, radiation therapy alone or in combination at the hospital. (3) Patients must be at least 20 years old. (4) Patients who have received a full explanation of the study and have given their consent.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from the study (1) Patients who have difficulty undergoing InBody testing. (2) Patients with psychosis or psychiatric symptoms that make it difficult for them to participate in the study. (3) Other cases in which the investigator or subinvestigator determines that participation in the study is inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in progression-free survival with and without sarcopenia | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in overall survival with and without sarcopenia Difference in response rate by sarcopenia Adverse events Analysis of blood samples for inflammatory cytokines and myokines | — |
Countries
Japan
Contacts
Public ContactSatoshi Watanabe
Niigata University Graduate School of Medical and Dental Sciences Department of Respiratory Medicine and Infectious Diseases
Outcome results
None listed